ArticleAnnals of clinical and translational neurology2026
Tracking Motor Progression and Device-Aided Therapy Eligibility in Parkinson's Disease.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tracking Motor Progression and Device-Aided Therapy Eligibility in Parkinson's Disease.Annals of clinical and translational neurology · 2026Article
- A modified Delphi consensus study to support and enhance Parkinson's disease management.Journal of Parkinson's disease · 2026Article
- Timing of device-aided therapy initiation in Parkinson's disease: reference estimates for healthcare planning and biological heterogeneity.Clinical parkinsonism & related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo characterise the progression of motor symptoms and identify eligibility for device-aided therapies in Parkinson's disease, using both the 5-2-1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
methodsWe analysed 1205 individuals with sporadic and genetic Parkinson's disease from the Parkinson's Progression Markers Initiative (mean follow-up: 5.6 ± 4.3 years). Kaplan-Meier analysis estimated time to meeting the 5-2-1 criteria (five or more daily levodopa doses, two or more hours of OFF time, or one or more hours of troublesome dyskinesia) and a stricter definition of eligibility for device-aided therapy based on disabling, medication-refractory symptoms and/or tremor. In the sporadic Parkinson's disease subgroup (n = 943), we assessed therapy initiation and clinical suitability, including potential contraindications. Genetic subgroup analyses explored differences in progression, eligibility timing and treatment uptake.
resultsAmong individuals with sporadic Parkinson's disease, 257 (27.3%) met the 5-2-1 criteria, with 25%, 50% and 75% doing so by 5.3, 8.2 and 10.7 years, respectively. A total of 176 (18.6%) met stricter eligibility criteria, with 50% doing so by 12 years. Only 25% of those meeting the 5-2-1 criteria initiated device-aided therapy within 6.8 years. Most had no contraindications. Deep brain stimulation was the most used therapy. GBA and SNCA carriers met criteria earlier. LRRK2 carriers were more likely to initiate therapy, while PRKN carriers were less likely to meet eligibility thresholds.
interpretationEligibility for device-aided therapy is common but underutilised. These findings highlight missed opportunities and support earlier, genotype-informed treatment planning in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.